MKI67 and breast carcinoma: Major steps toward a harmonization of Ki-67 scoring in breast cancer, however, have been already made [9, 23–25], and it may be predicted that Ki-67 assessment, with strict adherence to the international recommendations, will ultimately be included among the clinically useful biological parameters for the best treatment of patients with breast carcinoma.